Cardiac Neuroendocrine Tumours

The 2017 Toronto Cardiac Tumour Conference
Dr Robert Cusimano

The National Post
Meet the ace Canadian heart surgeon who ‘does the stuff other doctors are too scared to do’ – January 20, 2016
Fairchild TV
Heart Cancer
The Heart of the Matter – The Sunday Edition

Conference Goal

This programme will focus on the evaluation and treatment of primary neuroendocrine tumours of the heart. Topics will cover imaging modalities used in diagnosis, surgical options and operations, chemotherapeutic treatments and options, and pathological considerations of these rare tumours.


By the end of the conference, the participant will be able to:

  • Interpret the workup of a patient with a primary neuroendocrine tumour of the heart
  • Describe the characteristics that determine the cardiac lesion and know the surgical options for resection
  • Know which imaging modalities are best for determination of operability and the shortcoming of one modality over another
  • Describe the role of neo-adjuvent therapy and new therapies for a neuroendocrine tumour of the heart
  • Identify the limitations of pathological examination


Continuing Professional Development (CPD), Faculty of Medicine, University of Toronto, is fully accredited by the Committee on Accreditation of Continuing Medical Education (CACME), a subcommittee of the Committee on Accreditation of Canadian Medical Schools (CACMS). This standard allows CPD to review and assess educational activities based on the criteria established by The College of Family Physicians of Canada and the Royal College of Physicians and Surgeons of Canada.

As a result of a reciprocal agreement between the Royal College of Physicians and Surgeons of Canada, The American Medical Association, and The European Union for Medical Specialties (EUMS), CPD is permitted to assign respective credits.

Faculty Disclosure

It is the policy of University of Toronto, Faculty of Medicine, Continuing Professional Development to ensure balance, independence, objectivity, and scientific rigor in all its individually accredited or jointly accredited educational programs. Speakers and/or planning committee members, participating in University of Toronto accredited programs, are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships within the last FIVE (5) years with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of facts. It remains for the audience to determine whether the speaker's outside interests may reflect a possible bias in either the exposition or the conclusions presented.